Desmopressin - Elea

Drug Profile

Desmopressin - Elea

Alternative Names: DDAVP

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elea
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cancer metastases; Haemorrhage

Most Recent Events

  • 20 Sep 2017 Desmopressin is at phase II development stage for Haemorrhage (in patients with colorectal cancer with rectal bleeding) in Argentina (IV)
  • 01 Aug 2017 Elea completes a phase II trial in Haemorrhage (in patients with colorectal cancer with rectal bleeding) in Argentina (IV) (NCT01623206)
  • 31 Jul 2015 Elea completes a phase II trial in Cancer metastases (Prevention) in Argentina (IV) (NCT01606072)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top